Our History

April: Official registration of Raifarm Company and launch of our first office in Moscow.
May: First client contracts signed.
August: Launch of our first office in Kiev, Ukraine.

March: Completion of first drug registration in Russia.
July: Completion of first drug registration in Ukraine.
September: Launch of Almaty, Kazakhstan office.

March: Completion of first drug registration in Kazakhstan.
June: Launch of New York, USA office.
November: Completion of first medical device registration in Russia.
December: Completion of first dietary supplement registration.

January: Introduction of new product launch service in Russian market.
April: Completion of 50th product registration in Russia.
August: Beginning of first pharma product distribution project in Kazakhstan.
December: Successful completion of 200th regulatory project.

March: Registration of first cosmetic product in Russia.
September: Sales begin for Raifarm’s own product line in Russia.
November: Launch of our first exclusive marketing project for a cardio product in Russia.
December: Sales launch of Raifarm products in Kazakhstan.
December: First product registrations in CIS countries (excluding Russia, Ukraine, and Kazakhstan).
December: Successful completion of 300th regulatory project.

January: Sales launch of Raifarm products in Ukraine
March: Launch of Copharm Company to provide marketing services for pharma product promotion in Russia.
June: Sponsorship of medical reward “Prizvanie” in Russia.
September: Product line extension in Kazakhstan, including introduction of drug, Angiox.
October: Acquisition of 100th client.

April: Sales launch of Neo-Penotran group of drugs in Russian.
July: Sales launch of Neo-Penotran group of drugs in Kazakhstan.
July: Registration of 100th pharmaceutical product.
February: Successful completion of 500th project.
November: Successful completion of 600th project.
December: Registration of 10th medical device belonging to 2b-3 class of risk. 

June: 75% of market in value reached by Angiox, in the segment of antithrombotic agents for stent angioplasty.
September: Sale of the 1,000,000th pack of Neo-Penotran group of drugs.
December: Acquisition of 125th client.
December: Sale of Copharm to Swiss company Acino Pharma AG. 

March: Successful completion of 700th project.
June: Registration of 125th pharmaceutical product.

January: Signing of first contract for product registration in the EU.
January: Signing of first contract for product registration in Turkey.
March: Successful completion of 800th project.
May: Signing of first contract for support of Russian GMP inspection.

March: Successful completion of 900th project.
March: Successful completion of first Russian GMP inspection.
March: Acquisition of 150th Client.
May: Registration of 20th medical device belonging to 2b-3 class of risk.
June: Receipt of our 1,000th order.
November: Signed 25th contract for the Russian GMP inspection.
December: Completion of 10th Russian GMP inspection.

January: Registration of 145th pharmaceutical product.
February: Start of 1100th consulting project.
February: Receipt of 15th GMP certificate.
March: Start of 35th Russian GMP inspection.
April: Acquisition of 160th Client.
April: Competition of 20th Russian GMP inspection.
May: Successful completion of 1000th project.
June: Registration of 150th pharmaceutical product.
September: New service added: Mock Audit before GMP inspection.
September: Start of 50th Russian GMP inspection.
September: Acquisition of 165th Client.
October: Competition of 30th Russian GMP inspection.

February: Acquisition of 170th Client.
May: Acquisition of 175th Client.
August: Completion of 50th GMP inspection.
September: Acquisition of 180th Client.
November: Completed 5th GMP mock audit.
November: Acquisition of 185th Client.

January: Acquisition of 190th Client.
March: Completion of 60th GMP inspection.
September: Completion of 70th GMP inspection.
December: Acquisition of 200th Client.

May: Acquisition of 205th Client.
May: Completion of 1100th project.
July: Acquisition of 210th Client.
September: Completion of 70th GMP inspection.
November: Acquisition of 215th Client.

April: 1st drug registered under EAEU procedure.
May: Completed 10th GMP mock audit.
June: 1st drug dossier aligned with EAEU requirements.
July: Acquisition of 210th Client.
August: Completed registration of 50th medical device.
November: Completion of 1200th project.
November: Acquisition of 220th Client.
November: Completed registration of 60th medical device.

February: Completion of 80th GMP inspection.
April: Acquisition of 225th Client.
June: 2nd drug registered under EAEU procedure.
July: Completed registration of 65th medical device.
September: Acquisition of 230th Client.